TABLE 5

Mean ± SE (of four time points) of isotopic enrichment of leucine and KIC in the arterial vein (A), femoral vein (FV), and hepatic vein (HV) at the baseline (150–180 min) and during the last 30 min (330–360 min) of the infusion (intervention)

[1-13C, 15N]leucine
Total [13C]leucine
[13C]KIC
AFVHVAFVHVAFVHV
NS
 Baseline4.60 ± 0.282.69 ± 0.173.10 ± 0.198.69 ± 0.326.72 ± 0.206.85 ± 0.225.89 ± 0.205.51 ± 0.196.09 ± 0.20
 Intervention4.11 ± 0.242.49 ± 0.182.89 ± 0.148.71 ± 0.257.06 ± 0.227.18 ± 0.206.34 ± 0.195.85 ± 0.236.52 ± 0.19
Ins
 Baseline4.35 ± 0.172.43 ± 0.092.81 ± 0.138.59 ± 0.226.68 ± 0.136.66 ± 0.186.19 ± 0.125.77 ± 0.116.32 ± 0.14
 Intervention6.77 ± 0.284.12 ± 0.153.94 ± 0.1911.30 ± 0.418.71 ± 0.207.99 ± 0.237.28 ± 0.196.83 ± 0.147.41 ± 0.21
LoAA/Ins
 Baseline5.01 ± 0.272.69 ± 0.273.29 ± 0.238.95 ± 0.506.62 ± 0.456.91 ± 0.396.06 ± 0.295.60 ± 0.336.34 ± 0.30
 Intervention3.80 ± 0.392.38 ± 0.242.76 ± 0.216.40 ± 0.615.27 ± 0.425.39 ± 0.394.91 ± 0.384.63 ± 0.345.06 ± 0.39
HiAA/Ins
 Baseline4.90 ± 0.372.87 ± 0.183.28 ± 0.248.91 ± 0.426.84 ± 0.216.97 ± 0.286.01 ± 0.265.50 ± 0.226.14 ± 0.27
 Intervention2.02 ± 0.161.52 ± 0.121.70 ± 0.133.74 ± 0.313.51 ± 0.293.59 ± 0.293.30 ± 0.233.25 ± 0.223.33 ± 0.25
Som/AA
 Baseline5.08 ± 0.453.11 ± 0.293.09 ± 0.189.20 ± 0.587.20 ± 0.416.67 ± 0.256.16 ± 0.255.85 ± 0.206.23 ± 0.23
 Intervention2.58 ± 0.131.89 ± 0.062.00 ± 0.085.14 ± 0.164.74 ± 0.124.66 ± 0.124.55 ± 0.344.42 ± 0.294.75 ± 0.36
Som/NS
 Baseline5.66 ± 0.313.13 ± 0.183.46 ± 0.209.85 ± 0.397.22 ± 0.307.10 ± 0.336.30 ± 0.265.72 ± 0.246.50 ± 0.25
 Intervention6.19 ± 0.313.31 ± 0.243.92 ± 0.2510.85 ± 0.397.81 ± 0.348.09 ± 0.377.03 ± 0.296.28 ± 0.267.34 ± 0.31
  • Data given as molar percent excess.